Results 101 to 110 of about 2,247 (204)

Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infections.

, 2018
Click on the Resource Link to access the article (may not be free).BACKGROUND: We evaluated safety and tolerability of tedizolid phosphate at the 200-mg once-daily dose approved for 6-day treatment of skin and skin-structure infections. RESEARCH DESIGN
Bidell, Monique R, Prokocimer, Philippe, Hardalo, Cathy, De Anda, Carisa, Anuskiewicz, Steven, Lodise, Thomas P, Flanagan, Shawn D   +6 more
core   +1 more source

Tedizolid inhibits MUC5AC production induced by methicillin-resistant Staphylococcus aureus in human airway epithelial cells [PDF]

, 2018
Nagasaki University (長崎大学)博士(医学)The innate immune system plays an important role in early immunity against respiratory tract infection. Although airway epithelial cells produce mucus to eliminate pathogens and irritants, hypersecretion of mucus is ...
武田, 和明
core  

Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy

, 2019
Introduction: Tedizolid phosphate is an oxazolidinone approved for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs) and active against methicillin-resistant Staphylococcus aureus.
Bassetti M, Castaldo N, Giacobbe DR, Castaldo, Nadia, Peghin M, Carnelutti, Alessia, Bassetti, Matteo, Peghin, Maddalena, Giacobbe, Daniele Roberto, Carnelutti A   +9 more
core   +1 more source

In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci

, 2012
Objectives: To compare the activity of tedizolid (formally known as torezolid and TR-700) with that of 15 agents against a collection of linezolid-resistant staphylococci (164 coagulase-negative staphylococci and 5 Staphylococcus aureus).
Morales Kucharski, María Gracia, Pena, Irene, Rodríguez-Avial, Icíar, Culebras, Esther, Picazo, Juan José, Betriu, Carmen   +5 more
core   +1 more source

Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary

, 2014
The novel oxazolidinone tedizolid phosphate is in late-stage clinical development. In an effort to improve efficacy and safety, the adverse event profile and safety aspects of tedizolid phosphate have been evaluated in several preclinical animal models ...
Prokocimer, Philippe, Das, Debaditya, Fang, Edward, Mehra, Purvi, Tulkens, Paul M.   +4 more
core   +1 more source

To evaluate safety and efficacy of tedizolid phosphate in the management of several skin infections [PDF]

Tedizolid Phosphate is an oxazolidinone-class antibiotic and is used for the treatment of acute bacterial skin and skin structure infections. it is a prodrug activated by plasma or intestinal phosphatases to tedizolid following administration of the drug
Mohammed, Abdul Aala, Omair Sohail Ahmed, Mohammed Abdul Ali, Omer wasiq   +3 more
core  

Tedizolid ve Omadasiklin’nin Tüberküloz Dışı Mikobakterilere karşı in vitro etkinliğinin araştırılması

, 2023
Tüberküloz Dışı Mikobakteriler (TDM), çevrede her yerde özellikle toprak ve su kaynaklarında bulunan, fırsatçı patojenlerdir. Tüberküloz Dışı Mikobakteri kaynaklı enfeksiyonlara karşı uygun ilaç rejimlerinin oluşturulabilmesi için antibiyotik ...
Özçatalkaya, Nazlı Ece, Çiftçi, Elif, Şatana, Dilek, Türkkal, Seda, Yaman, Görkem   +4 more
core  

New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?

Pharmaceutics
Multidrug-resistant tuberculosis (MDR-TB) is a global health concern. Standard treatment involves the use of linezolid, a repurposed oxazolidinone. It is associated with severe adverse effects, including myelosuppression and mitochondrial toxicity.
Ricky Hao Chen, Andrew Burke, Jin-Gun Cho, Jan-Willem Alffenaar, Lina Davies Forsman   +4 more
doaj   +1 more source

Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.

, 2015
Tedizolid, a novel oxazolidinone with activity against a wide range of Gram-positive pathogens, was evaluated in two noninferiority phase 3 acute bacterial skin and skin structure infection trials.
Prokocimer, Philippe, Shorr, Andrew F, De Anda, Carisa, Das, Anita F, Fang, Edward, Corey, G Ralph, Lodise, Thomas P   +6 more
core   +1 more source

A tedizolid-foszfát (Sivextro®) in vitro hatékonyságának vizsgálata methicillin rezisztens Staphylococcus aureus (MRSA) törzseken

, 2016
A dolgozatomban egy új antibiotikum, a tedizolid hatását vizsgáltam MRSA baktériumokon. A methicillin rezisztens Staphylococcus aureus nagyon elterjedt baktérium és számos kórképet idéz elő.
Nagy, Jolán Erika
core